ZOMDF (Zomedica) Research & Development: $6.47 Mil (TTM As of Mar. 2026)


What is Zomedica Research & Development?

Zomedica ZOMDF -5.00% Research & Development is $6.47 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zomedica's Research & Development for the three months ended in Mar. 2026 was $1.15 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $6.47 Mil.

Zomedica  (OTCPK:ZOMDF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zomedica Research & Development Related Terms

Zomedica Research & Development Historical Data

* Premium members only.

The historical data trend for Zomedica's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Research & Development Chart

Zomedica Annual Data
Trend Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.67 2.58 5.74 7.27 7.17

Zomedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 1.89 1.78 1.64 1.15

Zomedica Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $6.47 Mil mean?
Zomedica (ZOMDF) has a Research & Development of $6.47 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zomedica and its competitors.
Is Zomedica's Research & Development too high?
Zomedica's current Research & Development is $6.47 Mil.
How does Zomedica's Research & Development compare to RPID and STIM?
Zomedica's Research & Development of $6.47 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zomedica and its competitors. Zomedica's current Research & Development is $6.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.19, compared to a current price of $0.10 — trading 50% below its estimated fair value. The current Research & Development is $6.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Research & Development is $6.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.